Fibrocel Science

FCSC NASDAQ
1.875
+0.035
+1.90%
已收盘, 16:00 05/24 EDT
开盘
1.800
昨收
1.840
最高
1.900
最低
1.800
成交量
4.27万
成交均量(3M)
96.29万
52周最高
5.17
52周最低
1.450
换手率
0.44%
市值
1,824.81万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Fibrocel Science FCSC股票价格,Fibrocel Science股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
展开 >

最近浏览

名称
价格
涨跌幅